Document Classification

Section Type: RESULTS

Text: Treatment with obinutuzumab-chlorambucil or rituximab-chlorambucil, as compared with chlorambucil monotherapy, increased response rates and prolonged progression-free survival (median progression-free survival, 26. 7 months with obinutuzumab-chlorambucil vs. 11. 1 months with chlorambucil alone ; hazard ratio for progression or death, 0. 18 ; 95 % confidence interval [CI], 0. 13 to 0. 24 ; P < 0. 001 ; and 16. 3 months with rituximab-chlorambucil vs. 11. 1 months with chlorambucil alone ; hazard ratio, 0. 44 ; 95 % CI, 0. 34 to 0. 57 ; P < 0. 001).